MX2014001717A - Composiciones inmunoterapeuticas de levadura-mucina 1 (muc1) y usos de las mismas. - Google Patents

Composiciones inmunoterapeuticas de levadura-mucina 1 (muc1) y usos de las mismas.

Info

Publication number
MX2014001717A
MX2014001717A MX2014001717A MX2014001717A MX2014001717A MX 2014001717 A MX2014001717 A MX 2014001717A MX 2014001717 A MX2014001717 A MX 2014001717A MX 2014001717 A MX2014001717 A MX 2014001717A MX 2014001717 A MX2014001717 A MX 2014001717A
Authority
MX
Mexico
Prior art keywords
yeast
immunotherapeutic compositions
muc1 immunotherapeutic
mucl
mucin
Prior art date
Application number
MX2014001717A
Other languages
English (en)
Other versions
MX352892B (es
Inventor
Zhimin Guo
Jeffrey Schlom
Alex Franzusoff
Kwong-Yok Tsang
Original Assignee
Globeimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Globeimmune Inc filed Critical Globeimmune Inc
Publication of MX2014001717A publication Critical patent/MX2014001717A/es
Publication of MX352892B publication Critical patent/MX352892B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/00117—Mucins, e.g. MUC-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0002—Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464469—Tumor associated carbohydrates
    • A61K39/46447—Mucins, e.g. MUC-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4727—Mucins, e.g. human intestinal mucin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins

Abstract

Se dan a conocer composiciones inmunoterapéuticas basadas en levadura que comprenden mucina 1 (MUC1), así como métodos para la prevención y/o tratamiento de cánceres caracterizados por expresión o sobreexpresión de mucina 1 (MUC1).
MX2014001717A 2011-08-17 2012-08-17 Composiciones inmunoterapeuticas de levadura-mucina 1 (muc1) y usos de las mismas. MX352892B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161524407P 2011-08-17 2011-08-17
PCT/US2012/051299 WO2013025972A1 (en) 2011-08-17 2012-08-17 Yeast-muc1 immunotherapeutic compositions and uses thereof

Publications (2)

Publication Number Publication Date
MX2014001717A true MX2014001717A (es) 2014-04-14
MX352892B MX352892B (es) 2017-12-13

Family

ID=47715495

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014001717A MX352892B (es) 2011-08-17 2012-08-17 Composiciones inmunoterapeuticas de levadura-mucina 1 (muc1) y usos de las mismas.

Country Status (12)

Country Link
US (3) US9533031B2 (es)
EP (1) EP2744918A4 (es)
JP (4) JP6122007B2 (es)
KR (1) KR102049928B1 (es)
CN (3) CN104024429B (es)
AU (3) AU2012296425B2 (es)
CA (1) CA2844500C (es)
IL (2) IL230863B (es)
MX (1) MX352892B (es)
RU (2) RU2642300C2 (es)
SG (1) SG10201607663YA (es)
WO (1) WO2013025972A1 (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2170384B1 (en) 2007-07-02 2016-04-13 Etubics Corporation Methods and compositions for producing an adenovirus vector for use with multiple vaccinations
EP2651439B1 (en) 2010-12-17 2018-09-19 Globeimmune, Inc. Compositions and methods for the treatment or prevention of human adenovirus-36 infection
SG192285A1 (en) 2011-02-12 2013-09-30 Globeimmune Inc Yeast-based therapeutic for chronic hepatitis b infection
HUE033491T2 (en) 2011-03-17 2017-12-28 Globeimmune Inc Yeast-Brachyury immunotherapy
SG10201605265TA (en) 2011-06-14 2016-08-30 Globeimmune Inc Yeast-Based Compositions and Methods for the Treatment or Prevention of Hepatitis Delta Virus Infection
CA2844500C (en) 2011-08-17 2022-05-10 Globeimmune, Inc. Yeast-muc1 immunotherapeutic compositions and uses thereof
ES2664325T3 (es) * 2012-01-03 2018-04-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Epítopos de CTL naturales y agonistas del antígeno tumoral de MUC1
AU2013281221B2 (en) 2012-06-26 2018-05-17 Biodesix, Inc. Mass-spectral method for selection, and de-selection, of cancer patients for treatment with immune response generating therapies
US9605276B2 (en) 2012-08-24 2017-03-28 Etubics Corporation Replication defective adenovirus vector in vaccination
MX2015013380A (es) 2013-03-19 2016-01-08 Globeimmune Inc Inmunoterapia para cordoma a base de levadura.
TWI728239B (zh) 2013-03-26 2021-05-21 美商環球免疫公司 治療或預防人類免疫缺乏病毒感染之組合物及方法
TWI654200B (zh) 2013-08-30 2019-03-21 環球免疫公司 治療或預防結核病的組合物及方法
JP6788500B2 (ja) * 2013-10-23 2020-11-25 アメリカ合衆国 Ｍｕｃ１−ｃ癌タンパク質のｈｌａ−ａ２４アゴニストエピトープ及び組成物及び使用方法
AU2015243256B2 (en) 2014-04-11 2020-11-05 Globeimmune, Inc. Yeast-based immunotherapy and type I interferon sensitivity
EP3236995A4 (en) 2014-12-23 2018-07-18 University of Maryland, Baltimore Muc1 decoy peptides for treatment and prevention of bacterial infections
CA2974237C (en) * 2015-01-09 2021-07-20 Etubics Corporation Methods and compositions for combination immunotherapy
CN107530383A (zh) 2015-01-09 2018-01-02 埃图比克斯公司 用于埃博拉病毒疫苗接种的方法和组合物
US11497767B2 (en) 2015-02-18 2022-11-15 Enlivex Therapeutics R&D Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11318163B2 (en) 2015-02-18 2022-05-03 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11596652B2 (en) 2015-02-18 2023-03-07 Enlivex Therapeutics R&D Ltd Early apoptotic cells for use in treating sepsis
US11512289B2 (en) 2015-02-18 2022-11-29 Enlivex Therapeutics Rdo Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11304976B2 (en) 2015-02-18 2022-04-19 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11000548B2 (en) 2015-02-18 2021-05-11 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11149087B2 (en) 2015-04-20 2021-10-19 Etubics Corporation Methods and compositions for combination immunotherapy
EP3285877B1 (en) 2015-04-21 2022-10-19 Enlivex Therapeutics Rdo Ltd Therapeutic pooled blood apoptotic cell preparations and uses thereof
CA2994272C (en) 2015-08-03 2023-08-22 Globeimmune, Inc. Modified yeast-brachyury immunotherapeutic compositions
EP3383427A4 (en) * 2015-12-04 2019-11-27 Mayo Foundation for Medical Education and Research METHODS AND VACCINES FOR INDUCING IMMUNE RESPONSES OF MULTIPLE DIFFERENT CMH MOLECULES
US20190183870A1 (en) 2016-01-05 2019-06-20 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Combination of histone deacetylase inhibitor and immunotherapy
HUE051722T2 (hu) * 2016-01-19 2021-03-29 Pfizer Rák elleni oltóanyagok
WO2017136342A1 (en) 2016-02-02 2017-08-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Fulvestrant for inducing immune-mediated cytotoxic lysis of cancer cells
CA3014885A1 (en) 2016-02-18 2017-08-24 Enlivex Therapeutics Ltd. Combination immune therapy and cytokine control therapy for cancer treatment
CA3018741A1 (en) 2016-03-24 2017-12-28 Nantcell, Inc. Sequence arrangements and sequences for neoepitope presentation
KR102306403B1 (ko) 2017-04-24 2021-09-28 난트셀, 인크. 표적화된 네오에피토프 벡터 및 그에 관한 방법 (targeted neoepitope vectors and methods therefor)
US20210154250A1 (en) * 2018-05-15 2021-05-27 Globeimmune, Inc. Lysates of recombinant yeast for inducing cellular immune responses
US11857620B2 (en) 2020-03-11 2024-01-02 Immunitybio, Inc. Method of inducing immunity against SARS-CoV-2 using spike (s) and nucleocapsid (N)-ETSD immunogens delivered by a replication-defective adenovirus
US20210284716A1 (en) 2020-03-11 2021-09-16 Immunitybio, Inc. ACE2-Fc Trap
EP4135753A1 (en) * 2020-04-17 2023-02-22 The Trustees of Columbia University in the City of New York Methods, compositions and uses thereof for reversing sacropenia
CN113214210B (zh) 2021-05-10 2022-03-04 合肥立方制药股份有限公司 一种二氢槲皮素的制备方法
CN113185485B (zh) 2021-05-10 2022-03-04 合肥立方制药股份有限公司 一种二氢槲皮素的半合成方法

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2486400B1 (fr) 1980-07-09 1986-05-30 Univablot Medicaments a base de levures ou de leurs extraits insolubles
NZ199722A (en) 1981-02-25 1985-12-13 Genentech Inc Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain
US4775622A (en) 1982-03-08 1988-10-04 Genentech, Inc. Expression, processing and secretion of heterologous protein by yeast
US5310654A (en) 1985-07-31 1994-05-10 The Board Of Trustees Of The Leland Stanford Junior University Method for determining virulence of Yersinia
US5234830A (en) 1988-02-03 1993-08-10 Suntory Limited DNA encoding a KEX2 endoprotease without a C-terminal hydrophobic region
IL95019A0 (en) 1989-08-09 1991-06-10 Mycogen Corp Process for encapsulation of biologicals
US5413914A (en) 1993-07-07 1995-05-09 The Regents Of The University Of Colorado Yeast assay to identify inhibitors of dibasic amino acid processing endoproteases
US5830463A (en) 1993-07-07 1998-11-03 University Technology Corporation Yeast-based delivery vehicles
US5858378A (en) 1996-05-02 1999-01-12 Galagen, Inc. Pharmaceutical composition comprising cryptosporidium parvum oocysts antigen and whole cell candida species antigen
EP1012276A2 (en) 1997-02-24 2000-06-28 Therion Biologics Corporation Recombinant pox virus for immunization against muc1 tumor-associated antigen
DE19758400A1 (de) 1997-12-30 1999-07-01 Max Delbrueck Centrum Tumorvakzine für MUC1-positive Karzinome
AU774076C (en) 1998-12-09 2005-04-14 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The A recombinant vector expressing multiple costimulatory molecules and uses thereof
DE19906615A1 (de) * 1999-02-17 2000-09-28 Hanisch Franz Georg Peptid-Varianten des Tumormarkers MUC1 und ihre Verwendung
DE60030450T2 (de) * 1999-09-08 2007-08-30 Transgene S.A. Von MUC-1 abgeleitete Peptide
DE10006753A1 (de) 2000-02-15 2001-08-16 Zeiss Carl Dreh-Schwenkeinrichtung für den Tastkopf eines Koordinatenmeßgerätes
US20020044948A1 (en) 2000-03-15 2002-04-18 Samir Khleif Methods and compositions for co-stimulation of immunological responses to peptide antigens
US8153414B2 (en) 2000-04-06 2012-04-10 Allertein Therapeutics, Llc Microbial delivery system
WO2002039951A2 (en) 2000-11-15 2002-05-23 Globe Immune, Inc. Yeast-dentritic cell vaccines and uses thereof
JP2006512047A (ja) * 2002-06-11 2006-04-13 グラクソスミスクライン　バイオロジカルズ　ソシエテ　アノニム 免疫原性組成物
AU2003251531A1 (en) * 2002-06-14 2003-12-31 Diadexus, Inc. Compositions and methods relating to breast specific genes and proteins
JP4914990B2 (ja) * 2002-12-16 2012-04-11 グローブイミューン，インコーポレイテッド 動物を癌から守るための治療用組成物
US7439042B2 (en) 2002-12-16 2008-10-21 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
US7696306B2 (en) 2003-07-11 2010-04-13 Board of Agents of the University of Nebraska Compositions and methods for preventing or treating cancer
GB0321615D0 (en) * 2003-09-15 2003-10-15 Glaxo Group Ltd Improvements in vaccination
EP1687322B1 (en) * 2003-11-12 2017-02-08 The Government of the United States of America, represented by the Secretary, Department of Health and Human Services Custom vectors for treating and preventing pancreatic cancer
CA2544946A1 (en) * 2003-11-24 2005-03-06 Sidney Kimmel Cancer Center Mucin antigen vaccine
US8828957B2 (en) * 2003-12-11 2014-09-09 Microvax, Llc Methods for generating immunity to antigen
JP2008504219A (ja) * 2003-12-11 2008-02-14 シドニー キンメル キャンサー センター 抗原に対する免疫を生じさせる方法
ES2616337T3 (es) 2003-12-12 2017-06-12 Government Of The United States Of America, As Repr. By The Secr. Of The Dept. Of Health And Human Services And His Successors Un epítopo de linfocito T citotóxico humano y su epítopo agonista del número no variable de secuencias de repetición en tándem de MUC-1
WO2007008780A2 (en) * 2005-07-11 2007-01-18 Globeimmune, Inc. Compositions and methods for eliciting an immune response to escape mutants of targeted therapies
US20070172503A1 (en) 2005-12-13 2007-07-26 Mycologics,Inc. Compositions and Methods to Elicit Immune Responses Against Pathogenic Organisms Using Yeast Based Vaccines
AU2007208218A1 (en) * 2006-01-23 2007-08-02 Recopharma Ab Production of proteins carrying oligomannose or human-like glycans in yeast and methods of use thereof
TW201412329A (zh) 2006-02-02 2014-04-01 Globeimmune Inc 用於誘發免疫反應之以酵母菌爲基礎之疫苗
KR20090008290A (ko) 2006-03-27 2009-01-21 글로브이뮨 Ｒａｓ 돌연변이와 그에 관련된 조성물 및 방법
JP5570819B2 (ja) 2007-02-02 2014-08-13 グローブイミューン，インコーポレイテッド 酵母を含む組成物および酵母を増殖させる方法
MX2009010066A (es) 2007-03-19 2009-10-12 Globeimmune Inc Composiciones y metodos para la ablacion especifica de la evasion mutacional de terapias especificas para cancer.
US20100278873A1 (en) 2007-11-08 2010-11-04 David Avigan Stimulation of anti-tumor immunity using dendritic cell/tumor cell fusions and anti-cd3/cd28
US8728489B2 (en) 2008-09-19 2014-05-20 Globeimmune, Inc. Immunotherapy for chronic hepatitis C virus infection
CA2741065C (en) * 2008-10-17 2017-04-25 Dana-Farber Cancer Institute, Inc. Muc-1 cytoplasmic domain peptides as inhibitors of cancer
WO2010065626A1 (en) 2008-12-02 2010-06-10 Globeimmune, Inc. Genotyping tools, methods and kits
KR102019728B1 (ko) * 2009-04-17 2019-09-09 글로브이뮨 암에 대한 병용 면역요법 조성물 및 방법
EP2477647B1 (en) 2009-09-14 2016-01-13 The Regents of the University of Colorado Modulation of yeast-based immunotherapy products and responses
WO2011115914A1 (en) 2010-03-14 2011-09-22 Globeimmune, Inc. Pharmacogenomic and response-guided treatment of infectious disease using yeast-based immunotherapy
WO2012019127A2 (en) 2010-08-05 2012-02-09 The Regents Of The University Of Colorado Combination yeast-based immunotherapy and arginine therapy for the treatment of myeloid-derived supressor cell-associated diseases
EP2651439B1 (en) 2010-12-17 2018-09-19 Globeimmune, Inc. Compositions and methods for the treatment or prevention of human adenovirus-36 infection
SG192285A1 (en) 2011-02-12 2013-09-30 Globeimmune Inc Yeast-based therapeutic for chronic hepatitis b infection
HUE033491T2 (en) 2011-03-17 2017-12-28 Globeimmune Inc Yeast-Brachyury immunotherapy
SG10201605265TA (en) 2011-06-14 2016-08-30 Globeimmune Inc Yeast-Based Compositions and Methods for the Treatment or Prevention of Hepatitis Delta Virus Infection
CA2844500C (en) 2011-08-17 2022-05-10 Globeimmune, Inc. Yeast-muc1 immunotherapeutic compositions and uses thereof

Also Published As

Publication number Publication date
JP6122007B2 (ja) 2017-04-26
EP2744918A4 (en) 2015-06-10
US20130315941A1 (en) 2013-11-28
CN114617958A (zh) 2022-06-14
US20170224794A1 (en) 2017-08-10
CN104024429B (zh) 2019-06-04
US10188714B2 (en) 2019-01-29
AU2012296425B2 (en) 2017-07-20
US11065318B2 (en) 2021-07-20
IL230863B (en) 2018-02-28
AU2017248462A1 (en) 2017-11-02
IL257533B (en) 2019-05-30
MX352892B (es) 2017-12-13
AU2017248462B2 (en) 2019-10-10
JP6571822B2 (ja) 2019-09-04
CN104024429A (zh) 2014-09-03
SG10201607663YA (en) 2016-11-29
JP2014524445A (ja) 2014-09-22
IL257533A (en) 2018-04-30
US9533031B2 (en) 2017-01-03
CA2844500C (en) 2022-05-10
RU2642300C2 (ru) 2018-01-24
JP2019194261A (ja) 2019-11-07
AU2020200137B2 (en) 2022-05-19
JP2017122120A (ja) 2017-07-13
NZ622335A (en) 2016-07-29
CA2844500A1 (en) 2013-02-21
CN109010809A (zh) 2018-12-18
US20190231859A1 (en) 2019-08-01
WO2013025972A1 (en) 2013-02-21
IL230863A0 (en) 2014-03-31
KR20140083987A (ko) 2014-07-04
RU2014109741A (ru) 2015-09-27
JP6306238B2 (ja) 2018-04-04
JP2018115173A (ja) 2018-07-26
AU2020200137A1 (en) 2020-01-30
AU2012296425A1 (en) 2014-04-03
EP2744918A1 (en) 2014-06-25
BR112014003477A2 (pt) 2017-10-17
RU2017143985A (ru) 2019-02-14
KR102049928B1 (ko) 2019-11-28

Similar Documents

Publication Publication Date Title
MX352892B (es) Composiciones inmunoterapeuticas de levadura-mucina 1 (muc1) y usos de las mismas.
MX2013010475A (es) Composiciones inmunoterapeuticas de levadura-brachyuri.
PH12014502697B1 (en) New diazaspirocycloalkane and azaspirocycloalkane
GEP201706695B (en) Substituted 4-phenyl-pyridi-nes for the treatment of nk-1 receptor related diseases
MY184101A (en) Indoles
MX360404B (es) Compuestos para inhibir la proliferacion celular en canceres transmitidos por egfr.
EP2714081A4 (en) METHODS, COMPOSITIONS AND KIT FOR CREAM TREATMENT
IN2012DN03883A (es)
IN2012DN02081A (es)
MX2014009289A (es) Anticuerpos c1orf32 y usos de los mismos para el tratamiento del cancer.
MX2011014019A (es) Derivados de diazahomoadamantano y sus metodos de uso.
MX2012010434A (es) Compuestos y composiciones novedosas para atacar a las celulas madre del cancer.
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
MX2015007097A (es) Nuevas fenil-piridinas/pirazinas bi-anulares para el tratamiento de cancer.
WO2013022991A3 (en) Methods and compositions relating to p62 for the treatment and prophylaxis of cancer
MY157341A (en) Methods and compositions for treating lung cancer
MX354988B (es) Formulaciones de anticuerpo y metodos.
MX367393B (es) Composiciones antifungicas para el tratamiento de piel y uñas.
WO2012017321A3 (en) Treatment for dyslipidemia
WO2012170742A3 (en) Treatment and prevention of cancer with hmgb1 antagonists
AU2016204389A1 (en) Kinase inhibitors for the treatment of cancer
MX2021008225A (es) Composiciones y metodos para tratamiento de crecimiento celular anormal.
MX2013003859A (es) Polimorfos de picropodofilina b o c para su uso en la terapia del cancer.
MX2013000539A (es) Nuevas formulaciones de analogos 14-epi de la vitamina d.
MX2011010046A (es) Derivados de diaminopteridina.

Legal Events

Date Code Title Description
FG Grant or registration